The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma.
Abstract
PURPOSE: To determine the absolute and relative value of microvessel density (MVD), p53 and c-erbB-2 protein expression, peritumoral lymphatic vessel invasion (PLVI), and conventional prognosticators in predicting relapse-free (RFS) and overall survival (OS) rates in patients with node-negative breast carcinoma (NNBC). PATIENTS AND METHODS: We monitored 254 consecutive patients with NNBC for a median of 62 months. Intratumoral MVD was measured after microvessels were immunostained using anti-CD31 antibody. p53 and c-erbB-2 protein and hormone receptors were also determined immunocytochemically. Results were analyzed by both univariate and multivariate statistical analysis. RESULTS: Univariate analysis showed that MVD was significantly predictive of both RFS (odds ratio [OR], 8.30; P = .0001) and OS (OR, 4.50; P = .012) when tested as a continuous or dichotomous variable. Likewise, tumor size (OR, 3.16; P = .0012), PLVI (OR, 4.36; P = .0009), estrogen receptor (ER) status (OR, 2.35; P = .016), progesterone receptor (PR) status (OR, 2.00; P = .017), and expression of p53 protein (OR, 2.82; P = .004) were significantly associated with RFS. Tumor size (OR, 3.80; P = .0038) and expression of p53 protein (OR, 2.58; P = .024) were significantly associated with OS by univariate analysis. Multivariate analysis showed that MVD (P = .0004), p53 protein expression (P = .0063), tumor size (P = .0144), and PLVI (P = .0033) were all significant and independent prognostic factors for RFS. However, only tumor size (P = .004) and MVD (P = .047) were independent predictors for OS. c-erbB2 expression was not associated with outcome by either univariate or multivariate analysis. CONCLUSION: MVD, p53 expression, PLVI, and tumor size are independent prognostic indicators of recurrence, which are useful in selection of high-risk NNBC patients who may be eligible to receive adjuvant therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
Self-citationA Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,531
Mutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Signer, S. H., Davidson, N., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,733
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Weidner, N., Folkman, J., Pozza, F., Bevilacqua, P., Allred, E. N., Moore, D. H., Meli, S., & Gasparini, G. (1992) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/84.24.1875 · Cited by 1,775
Self-citationWeinberg, R. A. (1991) · Science · doi:10.1126/science.1659741 · Cited by 1,756
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.
Weidner, N., Carroll, P. R., Flax, J. D., Blumenfeld, W., & Folkman, J. (1993) · PubMed Central · Cited by 1,620
Self-citationVeronesi, U., Saccozzi, R., Del Vecchio, M., Banfi, A., Clemente, C., De Lena, M., Gallus, G., Greco, M., Luini, A., Marubini, E., et al. (1981) · New England Journal of Medicine · doi:10.1056/nejm198107023050102 · Cited by 1,599
Self-citationFisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., Dimitrov, N. V., Wolmark, N., Wickerham, D. L., Fisher, E. R., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200802 · Cited by 1,464
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., & Folkman, J. (1990) · Nature · doi:10.1038/348555a0 · Cited by 1,299
Horak, E. R., Klenk, N., Leek, R., LeJeune, S., Smith, K., Stuart, N., Harris, A. L., Greenall, M., & Stepniewska, K. (1992) · The Lancet · doi:10.1016/0140-6736(92)93150-l · Cited by 800
Allred, D. C., Clark, G. M., Elledge, R., Fuqua, S. A. W., Brown, R. W., Chamness, G. C., Osborne, C. K., & McGuire, W. L. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.3.200 · Cited by 772
Thor, A. D., Moore, D. H., Edgerton, S. M., Kawasaki, E. S., Reihsaus, E., Lynch, H. T., Marcus, J. N., Schwartz, L., Chen, L.-C., Mayall, B. H., et al. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.11.845 · Cited by 723
Tumor invasion and metastasis: an imbalance of positive and negative regulation.
Liotta, L. A., & Stetler‐Stevenson, W. G. (1991) · PubMed · Cited by 705
Microvessel quantitation and prognosis in invasive breast carcinoma
Bosari, S., Lee, A. K. C., DeLellis, R. A., Wiley, B. D., Heatley, G. J., & Silverman, M. L. (1992) · Human Pathology · doi:10.1016/0046-8177(92)90344-3 · Cited by 549
Genetic Mechanisms of Tumor Suppression by the Human p53 Gene
Chen, P.-L., Chen, Y., Bookstein, R., & Lee, W.-H. (1990) · Science · doi:10.1126/science.2274789 · Cited by 518
Cathepsin D and Prognosis in Breast Cancer
Tandon, A. K., Clark, G. M., Chamness, G. C., Chirgwin, J. M., & McGuire, W. L. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002013220504 · Cited by 456
Parums, D. V., Cordell, J. L., Micklem, K., Heryet, A. R., Gatter, K. C., & Mason, D. Y. (1990) · Journal of Clinical Pathology · doi:10.1136/jcp.43.9.752 · Cited by 417
Neuroendocrine components of the bronchopulmonary tract: hyperplasias, dysplasias, and neoplasms.
Gould, V. E., Linnoila, R. I., Memoli, V. A., & Warren, W. H. (1983) · PubMed · Cited by 414
Efficacy of Adjuvant Chemotherapy in High-Risk Node-Negative Breast Cancer
Mansour, E. G., Gray, R., Shatila, A. H., Osborne, C. K., Tormey, D. C., Gilchrist, K. W., Cooper, M. R., & Falkson, G. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200803 · Cited by 352
Log-Logistic Regression Models for Survival Data
Bennett, S. (1983) · Applied Statistics · doi:10.2307/2347295 · Cited by 342
Isola, J., Visakorpi, T., Holli, K., & Kallioniemi, O.-P. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.14.1109 · Cited by 341
Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma
Toi, M., Tominaga, T., & Kashitani, J. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550305 · Cited by 315
Gasparini, G., Weidner, N., Maluta, S., Pozza, F., Boracchi, P., Mezzetti, M., Testolin, A., & Bevilacqua, P. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550507 · Cited by 305
Self-citationGasparini, G., Pozza, F., & Harris, A. L. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.15.1206 · Cited by 238
Self-citationp53 as an Independent Prognostic Marker in Lymph Node-Negative Breast Cancer Patients
Silvestrini, R., Benini, E., Daidone, M. G., Veneroni, S., Boracchi, P., Cappelletti, V., Fronzo, G. D., & Veronesi, U. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.12.965 · Cited by 236
Self-citationDifferent Tumor-Derived p53 Mutants Exhibit Distinct Biological Activities
Halevy, O., Michalovitz, D., & Oren, M. (1990) · Science · doi:10.1126/science.2218501 · Cited by 234
Gospodarowicz, D., & Thakral, K. K. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.2.847 · Cited by 175
Fox, S. B., Leek, R. D., Smith, K., Hollyer, J., Greenall, M., & Harris, A. L. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666186 · Cited by 170
Breast Cancer Therapy: Exercising All Our Options
DeVita, V. T. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200812 · Cited by 112
Barbareschi, M., Girlando, S., Mauri, F. A., Arrigoni, G., Laurino, L., Palma, P., & Doglioni, C. (1992) · The Journal of Pathology · doi:10.1002/path.1711660405 · Cited by 110
Self-citation
Cited by
Overview of resistance to systemic therapy in patients with breast cancer
Gonzalez-Angulo, A. M., Morales-Vasquez, F., & Hortobagyi, G. N. (2007) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-74039-3_1 · Cited by 904
Ziche, M., Morbidelli, L., Choudhuri, R., Zhang, H. T., Donnini, S., Granger, H. J., & Bicknell, R. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119451 · Cited by 915
The physiology of the lymphatic system
Swartz, M. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00150-8 · Cited by 737
Vermeulen, P. B., Gasparini, G., Fox, S. B., Toi, M., Martin, L., Mcculloch, P., Pezzella, F., Viale, G., Weidner, N., Harris, A. L., et al. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00379-6 · Cited by 729
Self-citationWeidner, N. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00666038 · Cited by 718
Self-citation
Metadata
- Authors
- Gasparini, G., Weidner, N., Bevilacqua, P., Maluta, S., Dalla Palma, P., Caffo, O., Barbareschi, M., Boracchi, P., Marubini, E., & Pozza, F.
- Venue
- Journal of Clinical Oncology
- Published
- 1994-03
- Volume
- 12
- Issue
- 3
- Pages
- 454-466
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2265031510
- Cited by
- 464
- References
- 32
- FWCI
- 21.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.